Silverback Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted immunotherapies for cancer and serious diseases. The company focuses on its proprietary ImmunoTAC platform, which enables the strategic pairing of linker-payloads with monoclonal antibodies to modulate disease-modifying pathways and deliver tissue-targeted therapeutics. Core products include immuno-oncology agents such as SBTX-101, an investigational therapy for solid tumors in Phase 1 clinical trials, as well as preclinical candidates SBTX-102 and SBTX-103 targeting breast and prostate cancers, respectively. Silverback also explores autoimmune disease treatments under its pipeline. Headquartered in Seattle, Washington, the company operates primarily in the U.S. market. In a major strategic development, Silverback Therapeutics merged with ARS Pharmaceuticals in an all-stock transaction completed in late 2022, after which the combined entity was renamed ARS Pharmaceuticals, Inc., and trades under the ticker SPRY. This merger brought significant capital of over $265 million to support the potential launch of neffy®, an intranasal epinephrine nasal spray for severe allergic reactions, currently under FDA review with a pending PDUFA date in 2023. Following this merger, Silverback shifted its strategic focus to the development and commercialization of neffy® alongside advancing its immunotherapy pipeline. Additionally, it discontinued previous oncology programs SBT6050 and SBT6290 and streamlined operations with a workforce reduction to extend its cash runway into the second half of 2026. The consolidated company now prioritizes both allergy treatment commercialization and its immuno-oncology development programs. Silverback operates principally in biotechnology research and development with a niche in immuno-oncology and immunology therapeutic areas. It partners strategically to enhance drug development and commercialization efforts. Founded in 2008, the company has built a strong portfolio leveraging its ImmunoTAC technology platform for systemic and targeted delivery of immune-modulating therapeutics, targeting primarily cancer and autoimmune disorders. Its recent merger and pivot towards allergy treatment mark significant shifts in the company’s operational and strategic trajectory. The company’s commercial and R&D activities span the U.S. pharmaceutical and biotechnology markets.
Company News
Head to Head Review: Evelo Biosciences (NASDAQ:EVLO) vs. Silverback Therapeutics (NASDAQ:SBTX)
Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 4.6% – Here’s What Happened
SkinBioTherapeutics receives Croda boost
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RMO
Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins
Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce
Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential
CLASS ACTION UPDATE for FB, ONTF and SBTX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
Why Are Silverback Therapeutics Shares Falling On Monday?
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference